Lung mass pathophysiology

Lung Mass Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Causes
Differentiating Lung Mass from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Diagnosis
Diagnostic Study of Choice
Evaluation of Lung Mass
Imaging of Lung Mass
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Lung mass pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Lung mass pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Lung mass pathophysiology
CDC on Lung mass pathophysiology
Lung mass pathophysiology in the news
Blogs on Lung mass pathophysiology
Directions to Hospitals Treating bone or soft tissue mass
Risk calculators and risk factors for Lung mass pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief:

Overview

A lung mass is defined as an opacity in the lungs that is more than 3 cms (or 1 ½ inches) in size. Lung opacity less than 3 cms are classified as lung nodules.

Genetics

EGFR mutations are seen in about 20%- 50% of lung adenocarcinoma (especially in Asian population)

• EGFR mutations are responsible for the constitutive activation of the tyrosine kinase.
• The most frequent mutations are present in exons 18e21 of the EGFR gene.
  • Other mutation involves translocations involving the anaplastic lymphoma kinase (ALK) tyrosine kinase are most frequently EML4-ALK fusions and are seen in estimated 10% of patients with lung adenocarcinoma.